Hahn Praises FDA Staff For Meeting User-Fee Goals While Adjusting To COVID-19
Executive Summary
In a 23 June blog post, FDA head Stephen Hahn issued a statement praising agency staff for continuing to meet their statutory obligations under MDUFA V considering the added difficulties of working through the coronavirus pandemic. While noting the agency is being creative in how it works in its new COVID-19 reality, he cautioned the FDA may not be able to meet those deadlines in the future if things continue as they are. Hahn also in his blog post addressed in-person inspections of manufacturing facilities.
You may also be interested in...
Pandemic Could Cause FDA To Miss User-Fee Deadlines
In a new temporary guidance document from the US FDA, the agency says while it’s still meeting its deadline obligations for premarket applications under its user-fee agreement with industry, it may end up missing future deadlines due to strains on the agency from COVID-19. In such cases, the FDA says it will get back to the sponsor about setting a new estimated deadline.
FDA’s Hahn Says The Agency Is Meeting Its MDUFA Review Goals – For Now
US FDA commissioner Stephen Hahn says in a 16 April communique that the agency is still performing “user-fee review activities” despite the ongoing coronavirus pandemic – but he warns that the FDA might not be able to do so “indefinitely.”
Compliance Corner: How To Survive An FDA ‘Desk Audit’ During The COVID-19 Crisis
A former US FDA investigations branch director explains how a paper-based “desk audit” would be performed by the agency in lieu of an on-site quality systems inspection. Last month the FDA hit the pause button on in-person inspections as the coronavirus pandemic rolls on.